Tag Archives: Kiran Mazumdar-Shaw
Spray and pray – the COVID-19 version
Kiran Mazumdar-Shaw is the head of Biocon, a company headquartered in Bengaluru and which has repurposed a drug called itolizumab – already approved to help manage severe chronic psoriasis in different markets – to manage cytokine release syndrome (CRS) in … Continue reading
Posted in Science
Tagged azithromycin, Biocon, chyavanprash, COVID-19, cytokine release syndrome, cytokine storm, favipiravir, hydroxychloroquine, Itolizumab, Kiran Mazumdar-Shaw, novel coronavirus, psoriasis, The Print
Comments Off on Spray and pray – the COVID-19 version
The matter of a journal’s reputation
Apparently (and surprisingly) The Telegraph didn’t allow Dinesh Thakur to respond to an article by Biocon employee Sundar Ramanan, in which Ramanan deems Thakur’s article about the claims to efficacy of the Biocon drug Itolizumab not being backed by enough data to have … Continue reading
Posted in Analysis, Science
Tagged Biocon, Björn Brembs, COVID-19, cytokine release syndrome, Dinesh Thakur, Drug Controller General of India, Itolizumab, Jammi Nagaraj Rao, journal impact factor, Kiran Mazumdar-Shaw, Newslaundry, phase II clinical trials, phase III clinical trials, prestige journals, prestigious journals, reputed journals, Seema Ahuja, Sundar Ramanan, The Telegraph
Comments Off on The matter of a journal’s reputation